Alliance Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Alok Sinha who wrote (357)	5/14/1999 10:54:00 PM
From: Cacaito	of 548

Dupont and ImaRx patent lawsuit against MolByos and Malllindckrodt. Check on prnewswire May 4. Fight is about US patent 5,547,656 relating low density gas filled microspheres Dupont/ImaRX(perflutren = Definity TM), pending FDA approval. Sonus has EchoGen (dodecafluoropentane) pending FDA approval. Echovist and Levovist (galactose based)from Schering apparently are poor contrast agents. Albunex from Malindcrodt is apparently a poor agent. But they also have Optisom (perfluropropane). Sonovue from Braco a poor agent (sulfur hexafluorine gas). Iodapamide ethyl ester, company? NC100100 from Nycomed is also in the race. From: Diagnostic Imaging, March 1999 pages 56-61. www.dimag.com I used the printed version. It seems to be a tough field. Allp at least has other applications in phase III. Schering seems to be with ALLP because their own product is not so efficient.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next